Co-Diagnostics and ReadyGo Collaborate to Evaluate Blood-Based Molecular Testing at the Point of Need, Starting with Ebola

Blood-based testing could open new markets for the Co-Dx® PCR platform, including HIV and hepatitis B and C Co-Diagnostics and ReadyGo target decentralized Ebola detection as the first application of their collaboration Combining GoCollect® sample preparation with Co-Dx PCR technology could bring blood-based molecular testing closer to patients Company to hold in-person press conference and live webcast today at 10:30 a.m. ET

SALT LAKE CITY , Sept. 16, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX ) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests and ReadyGo Diagnostics Ltd. ("ReadyGo"), a UK-based developer of field sample-preparation technology, today announced that the companies are collaborating to evaluate the potential use of ReadyGo's sample-preparation technology with the Co-Dx PCR platform for blood-based molecular testing at the point of need, with an initial focus on decentralized Ebola virus detection and outbreak response (the "Collaboration").

Establishing blood as a compatible sample type would extend the Co-Dx PCR platform beyond the swab-based testing it supports today and into a broad category of bloodborne pathogens that swab sampling cannot reach. The companies are evaluating two potentially complementary technologies: the Co-Dx® PCR platform*, a point-of-need PCR technology; and GoCollect® by ReadyGo, a field sample-preparation system that prepares blood samples for molecular testing at the point of need. The collaboration will assess whether the technologies can operate together as part of a streamlined workflow that prepares the sample, detects the virus, and supports the outbreak response as one connected approach. The collaboration builds on Co-Dx's earlier proof-of-concept work testing an Ebola assay using plasma as a sample type.

ReadyGo's GoCollect® technology is designed to prepare capillary blood samples for molecular testing through integrated sample-conditioning chemistry and plasma separation. Its collection chemistry is also intended to inactivate the virus at the point of collection, an important consideration for handling samples safely outside a laboratory. The companies are evaluating whether the resulting sample can be processed on the Co-Dx PCR platform, which is designed to bring molecular detection to decentralized settings where outbreaks occur and to synchronize results through Co-Dx cloud infrastructure. That compatibility has not yet been established and is the subject of the feasibility work now underway.

"We designed GoCollect for places where a laboratory isn't an option, where a sample either gets tested nearby or it doesn't get tested at all," said Ben Cobb, CEO of ReadyGo Diagnostics. "GoCollect takes sample collection and preparation into the field, and works seamlessly with platforms such as Co-Dx to create a complete sample-to-result molecular testing solution. Both technologies were designed around the same need, making high-quality molecular diagnostics practical outside conventional laboratory settings....